论文部分内容阅读
目的:评价丙酸倍氯米松鼻喷雾剂(商品名:伯克纳)治疗血管运动性鼻炎的临床疗效及安全性。方法:以曲安奈德鼻喷雾剂为对照药,采用开放性、随机对照方法治疗血管运动性鼻炎160例,剂量用法:丙酸倍氯米松鼻喷雾剂,鼻腔喷入,每次每鼻孔2揿,每日2次,每揿50μg;曲安奈德鼻喷雾剂,鼻腔喷入,每次每鼻孔2揿,每日2次,每揿55μg。疗程均为2周。结果:丙酸倍氯米松鼻喷雾剂临床疗效评价例数为100例,曲安奈德鼻喷雾剂临床疗效评价例数为60例,两药临床有效率分别为88%和80%,药物不良反应发生率分别为10%和13%。结论:丙酸倍氯米松鼻喷雾剂治疗血管运动性鼻炎安全、有效。
Objective: To evaluate the clinical efficacy and safety of beclomethasone dipropionate nasal spray (trade name: Berkana) in the treatment of vasomotor rhinitis. Methods: The triamcinolone acetonide nasal spray was used as the reference drug. An open and randomized controlled trial was used to treat 160 cases of vasomotor rhinitis. Dosage: Beclomethasone propionate nasal spray, nasal spray, , 2 times a day, each 揿 50μg; Triamcinolone nasal spray, nasal spray, each nostril 2 揿, 2 times a day, every 揿 55μg. The course of treatment is 2 weeks. Results: The clinical efficacy evaluation of beclometasone dipropionate was 100 cases. The clinical efficacy evaluation of triamcinolone acetonide nasal spray was 60 cases. The effective rates of the two drugs were 88% and 80%, respectively. Adverse drug reactions The incidence rates were 10% and 13% respectively. Conclusion: Beclomethasone propionate nasal spray is safe and effective in the treatment of vasomotor rhinitis.